Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI

Current and future applications

Thomas A. Hope, Ali Afshar-Oromieh, Matthias Eiber, Louise Emmett, Wolfgang P. Fendler, Courtney Lawhn-Heath, Steven Rowe

Research output: Contribution to journalArticle

Abstract

OBJECTIVE. The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION. PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.

Original languageEnglish (US)
Pages (from-to)286-294
Number of pages9
JournalAmerican Journal of Roentgenology
Volume211
Issue number2
DOIs
StatePublished - Aug 1 2018

Fingerprint

Prostatic Neoplasms
Patient Selection
human glutamate carboxypeptidase II
Positron Emission Tomography Computed Tomography
Therapeutics

Keywords

  • PET
  • PET/MRI
  • Prostate cancer
  • Prostate-specific membrane antigen

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI : Current and future applications. / Hope, Thomas A.; Afshar-Oromieh, Ali; Eiber, Matthias; Emmett, Louise; Fendler, Wolfgang P.; Lawhn-Heath, Courtney; Rowe, Steven.

In: American Journal of Roentgenology, Vol. 211, No. 2, 01.08.2018, p. 286-294.

Research output: Contribution to journalArticle

Hope, Thomas A. ; Afshar-Oromieh, Ali ; Eiber, Matthias ; Emmett, Louise ; Fendler, Wolfgang P. ; Lawhn-Heath, Courtney ; Rowe, Steven. / Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI : Current and future applications. In: American Journal of Roentgenology. 2018 ; Vol. 211, No. 2. pp. 286-294.
@article{c96b1d6f09e9440d9d62984926b8317c,
title = "Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: Current and future applications",
abstract = "OBJECTIVE. The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION. PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.",
keywords = "PET, PET/MRI, Prostate cancer, Prostate-specific membrane antigen",
author = "Hope, {Thomas A.} and Ali Afshar-Oromieh and Matthias Eiber and Louise Emmett and Fendler, {Wolfgang P.} and Courtney Lawhn-Heath and Steven Rowe",
year = "2018",
month = "8",
day = "1",
doi = "10.2214/AJR.18.19957",
language = "English (US)",
volume = "211",
pages = "286--294",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "2",

}

TY - JOUR

T1 - Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI

T2 - Current and future applications

AU - Hope, Thomas A.

AU - Afshar-Oromieh, Ali

AU - Eiber, Matthias

AU - Emmett, Louise

AU - Fendler, Wolfgang P.

AU - Lawhn-Heath, Courtney

AU - Rowe, Steven

PY - 2018/8/1

Y1 - 2018/8/1

N2 - OBJECTIVE. The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION. PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.

AB - OBJECTIVE. The purpose of this article is to describe the large number of radiotracers being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer. CONCLUSION. PSMA PET is a highly promising modality for the staging of prostate cancer because of its higher detection rate compared with that of conventional imaging. Both PET/CT and PET/MRI offer benefits with PSMA radiotracers, and PSMA PET findings frequently lead to changes in management. It is imperative that subsequent treatment changes be evaluated to show improved outcomes. PSMA PET also has potential applications, including patient selection for PSMA-based radioligand therapy and evaluation of treatment response.

KW - PET

KW - PET/MRI

KW - Prostate cancer

KW - Prostate-specific membrane antigen

UR - http://www.scopus.com/inward/record.url?scp=85052388103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052388103&partnerID=8YFLogxK

U2 - 10.2214/AJR.18.19957

DO - 10.2214/AJR.18.19957

M3 - Article

VL - 211

SP - 286

EP - 294

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 2

ER -